Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $40.60, above its previous 52-week high of $40.48 with 2.2 million shares traded as of 11:26 a.m. ET. Average volume has been 9.4 million shares over the past 30 days.
Bristol-Myers Squibb has a market cap of $66.36 billion and is part of the health care sector and drugs industry. Shares are up 23.5% year to date as of the close of trading on Monday.
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. The company has a P/E ratio of 34.8, above the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Bristol-Myers Squibb as a
. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full
52-week high stocks
or get investment ideas from our
It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE